CEO Vlad Vitoc Buys 100,000 MAIA Shares for $100,000 on the Open Market
MAIA sits 43% above its 52-week low of $0.87 on elevated volume (3.6× avg).
Summary
CEO Vlad Vitoc bought 100,000 MAIA shares for $100,000 at $1.00 in two open-market trades on November 13 and 16, lifting his direct stake to 1,149,121 shares.
Key Events · Ownership and Investor Activity · MAIA
-
CEO Open-Market Purchase
Vlad Vitoc bought 100,000 shares for $100,000 at $1.00 per share in two transactions: 60,400 shares on 2026-11-13 and 39,600 shares on 2026-11-16.
-
Stake Rises to 1.15M Shares
Post-transaction direct holdings are 1,149,121 shares; an additional 210,100 shares are held indirectly by his spouse, of which he disclaims beneficial ownership.
-
Timing After Positive Updates
The buying followed the 2026-11-09 10-Q, which showed the Q3 net loss narrowed to $7.18M from $8.90M, and the 2026-11-17 8-K reporting an 88% disease control rate in Phase 2 THIO-101 Part C.
-
Entry Price Below Market
The $1.00 purchase price compares with today's $1.24 stock price; the second tranche was executed at a weighted average of $0.9905 to $1.0000.
Analysis · MAIA · Life Sciences
Why it matters: the CEO put $100,000 of his own money into MAIA at $1.00 a share, just days after the company reported narrowed Q3 losses and updated Phase 2 THIO-101 data showing an 88% disease control rate in third-line NSCLC. The sum is modest relative to the company's size, but it is a real open-market purchase rather than an option exercise, and it lands right after two positive disclosures. With the stock at today's $1.24, the shares have already moved above his $1.00 entry price.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MAIA was trading at $1.24 on NYSE in the Life Sciences sector, with a market capitalization of approximately $77.2M. The 52-week trading range was $0.87 to $3.19. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.